News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
aol.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received a consensus "Buy" rating from analysts, with an average 12-month price target of $209.14, significantly above its current trading price of $154.93. Despite this positive sentiment, the company recently reported quarterly losses of $1.52 per share, missing consensus …
Palvella Therapeutics, Inc. (PVLA) has issued a new risk disclosure in the "Regulation" category, indicating a high degree of risk for potential shareholders. The company urges investors to carefully review its disclosed risks and uncertainties, which could materially impact investment value. Despite these warnings, …
Palvella Therapeutics reported significant progress in Q2 2026, advancing QTORIN rapamycin with compelling Phase 3 SELVA study results, a pre-NDA meeting with the FDA, and Rolling Review designation. The company is on track to complete the NDA submission for QTORIN rapamycin in 2026, targeting …
Palvella Therapeutics, Inc. (PVLA) published a slide deck in conjunction with their Q2 2026 earnings call, held on August 5, 2026. The company reported an EPS of -$1.52, missing estimates by $0.37, while revenue was $0.00, beating estimates by $0.00. This report was prepared …
Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that its Founder and CEO, Wes Kaupinen, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is a clinical-stage biopharmaceutical firm focused on developing novel therapies for …
Palvella Therapeutics, Inc. (PVLA) reported a Q2 loss of $21.9 million, or $1.52 per share, missing Wall Street expectations. Analysts surveyed by Zacks Investment Research had estimated a loss of $1.16 per share for the Wayne, Pennsylvania-based company. The financial data was generated by …
This article provides comprehensive information on Palvella Therapeutics, Inc. (PVLA) stock, including its current price, historical data, and a compilation of recent news and press releases. Key updates include the company's progress on its New Drug Application (NDA) for QTORIN rapamycin for microcystic lymphatic …
Palvella Therapeutics (PVLA) reported a Q2 net loss of $1.52 per share, which is wider than the FactSet estimate of a $1.07 loss. The company is a clinical-stage biopharmaceutical firm focused on rare genetic skin diseases, with its lead product candidate QTORIN rapamycin currently …
Palvella Therapeutics reported its second quarter 2026 financial results, highlighting significant progress in its clinical programs. Key updates include the submission of the first module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations, with a planned commercial launch in early 2027 …
Jennison Associates LLC has reported a 6.7% beneficial ownership stake in Palvella Therapeutics Inc., holding 960,619 shares of common stock as of June 30, 2026. The filing indicates Jennison has sole voting power and shared dispositive power over these shares. This disclosure, made via …
This article provides the enterprise value to EBITDA forward for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a financial data point presented within the TradingView platform, focused on the biotechnology sector. The content primarily lists navigation and footer elements of the TradingView …
Palvella Therapeutics' Chief Scientific Officer, Dr. Jeffrey Martini, will present at an FDA public workshop on August 5, 2026, to discuss drug repurposing for rare and chronic diseases. The workshop aims to explore methods for prioritizing FDA-approved drugs for new uses and address regulatory …
Palvella Therapeutics announced that its Chief Scientific Officer, Jeffrey Martini, Ph.D., will contribute to an upcoming FDA public workshop on drug repurposing on August 5, 2026. Dr. Martini will discuss evidence frameworks and regulatory approaches for advancing repurposed therapies, especially for rare diseases with …
Palvella Therapeutics' Chief Scientific Officer, Dr. Jeff Martini, will present at an FDA public workshop on drug repurposing on August 5, 2026. The meeting aims to explore strategies for selecting and prioritizing FDA-approved drugs for new uses, accelerating access to therapies for unmet medical …
BlackRock, Inc. has filed a Schedule 13G, disclosing a 5.7% beneficial ownership stake in Palvella Therapeutics, Inc. (PVLA) as of June 30, 2026. This ownership represents 812,953 shares of common stock, with BlackRock holding sole voting power over 796,317 shares and sole dispositive power …
This article provides a comprehensive stock analysis of Palvella Therapeutics Inc (PVLA), highlighting its strong fundamentals, high growth potential, and "Buy" ratings from analysts with a target price of $229.00. The company, a clinical-stage biopharmaceutical firm, is developing therapies for rare genetic skin diseases, …
This article provides a valuation analysis of Palvella Therapeutics Inc (PVLA), noting its current valuation score and P/E ratio. It highlights that the company ranks 41 out of 385 in the Biotechnology & Medical Research industry. The report also indicates that relevant data for …
Palvella Therapeutics (Nasdaq: PVLA) will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Management will host an investor conference call and webcast at 8:30 a.m. ET that day to discuss the results and provide a corporate update. …
Palvella Therapeutics will report its Q2 2026 financial results on August 4, 2026, before market open, followed by an investor conference call at 8:30 a.m. ET. The company will discuss its financial performance and provide a corporate update, focusing on its QTORIN™ platform for …
The article discusses the revenue breakdown of Palvella Therapeutics Inc (PVLA), stating that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company. It notes PVLA's current stock price, market cap, and P/E TTM. The content indicates …
Palvella Therapeutics Inc (PVLA) has a robust financial status with a current financial score of 6.80, ranking 202 out of 386 in the Biotechnology & Medical Research industry, however, its operating efficiency is low. The article notes that relevant financial data regarding quality of …
This article provides an overview of market sentiment for Palvella Therapeutics (PVLA), including analyst consensus, short interest, options flow, and insider activity. Analysts currently have a "Buy" consensus with an average price target of $161, projecting a 15.0% upside. The short float is noted …
This article details the shareholder structure of Palvella Therapeutics Inc (PVLA), listing its major shareholders and their respective proportions. It also provides institutional shareholding data over several quarters, showing the number of institutions, shares held, and proportional changes. Additionally, the article highlights recent shareholder …
This article provides historical dividend and stock split information for Palvella Therapeutics Inc (PVLA). It states that PVLA has not distributed any dividends in the past five years and lists stock split events, specifically an 80-to-1 merger on April 18, 2024. The company's current …
This article provides a financial overview of Palvella Therapeutics, Inc. (FWB:PI6) on the Frankfurt Stock Exchange, specifically highlighting its enterprise value to revenue forward metric. It also lists various products, services, and community features offered by TradingView, the platform on which the information is …
Search by ticker symbol or company name and select a result to open its chart.